Skip to main content

Table 2 Adverse Effects

From: Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial

 

TX (n = 65)

TE (n = 74)

 

Any Grade (%)

Grade 3–4 (%)

Any Grade (%)

Grade 3–4 (%)

Neutropenia

42(64.6)

18(47.6)

58(78.4)

25(33.8)

Anemia

15(23.1)

1(1.5)

18(24.3)

3(4.1)

Hand-foot syndrome

42(64.6)

13(20)

6(8.1)

0

Sensory neuropathy

27(41.6)

2(3.1)

34(45.9)

1(1.4)

Symptomatic heart failure

0

0

0

0

ALT/AST increased

12(18.5)

5(7.7)

20(27)

9(12.2)

Vomiting

18(27.7)

4(6.2)

22(29.7)

5(6.8)

Nausea

33(50.7)

3(4.6)

38(51.4)

5(6.8)

Diarrhea

12(18.5)

5(7.7)

10(13.5)

3(4.1)

Alopecia

50(76.9)

NA

68(91.9)

NA

Wound infection

3(4.6)

1(1.5)

2(2.7)

0

Leukemia

0

0

1

1(1.4))